Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (541-550 of 636) with videos related to

Pageof 64
Sort By:
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Circulation. Cardiovascular Quality and Outcomes|July 9, 2015
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 YearsKristian Kragholm, Sharif A Halim, Qinghong Yang, et al.
Journal of Vascular Surgery|October 1, 2021
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trialNicholas Govsyeyev, Mark R Nehler, Cecilia C Low Wang, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
American Heart Journal|November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillationZak Loring, Peter Shrader, Larry A Allen, et al.
European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Pageof 64

Showing results (541-550 of 636) with videos related to

Sort By:
Pageof 64
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Circulation. Cardiovascular Quality and Outcomes|July 9, 2015
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 YearsKristian Kragholm, Sharif A Halim, Qinghong Yang, et al.
Journal of Vascular Surgery|October 1, 2021
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trialNicholas Govsyeyev, Mark R Nehler, Cecilia C Low Wang, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
American Heart Journal|November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillationZak Loring, Peter Shrader, Larry A Allen, et al.
European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Pageof 64